表紙
市場調査レポート

中国のヘモフィルス・インフルエンザ菌b型(Hib)ワクチン産業の分析

Research Report on China's Haemophilus Influenza B (HIB) Vaccine Industry, 2013-2017

発行 China Research and Intelligence 商品コード 284094
出版日 ページ情報 英文 20 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
中国のヘモフィルス・インフルエンザ菌b型(Hib)ワクチン産業の分析 Research Report on China's Haemophilus Influenza B (HIB) Vaccine Industry, 2013-2017
出版日: 2013年09月22日 ページ情報: 英文 20 Pages
概要

当レポートでは、中国のヘモフィルス・インフルエンザ菌b型(Hib)ワクチン産業について調査分析し、発展環境、Hib感染症の流行状況、需要と供給の状況、主要メーカー、発展に影響を与える要因、市場予測などを提供して、概略以下の構成でお届けいたします。

第1章 中国のワクチン産業の発展環境

  • 経済環境
  • 政策環境
  • 中国の人口と構造
  • 中国の医療産業の概要
  • 中国のワクチン市場の概要

第2章 中国のHibワクチン産業の概要

  • 中国におけるHib感染症の流行状況
  • Hib共役ワクチンの概要
  • 中国におけるHibワクチンのワクチン接種ルール

第3章 中国のHibワクチン市場の分析

  • 供給状況
  • 市場規模

第4章 中国のHibワクチン市場における主要メーカー

  • Lanzhou Institute of Biological Products Co., Ltd.
  • Sanofi Pasteur
  • GSK China
  • Novartis Vaccines and Diagnostics S.R.L.

第5章 中国のHibワクチン産業の予測

  • 発展に影響を与える要因
  • 供給予測
  • 需要予測

図表

目次

Haemophilus influenza type B is a kind of haemophilus influenza with extremely strong invasiveness. Among all the serious infections caused by haemophilus influenzas, almost 90% were caused by haemophilus influenza type B.

According to the researches in recent years, HIB has become the first bacteria that will cause diseases on the respiratory tracts of children in China. It mainly causes lower respiratory infection and pneumonia. After infected by HIB, the risk of getting invasive diseases is related to one's HIB immune level. The prevalence rate of HIB antibody in infants is quite high, which mainly comes from mothers. Antibody titer reaches the highest point when infants are three to four months old. In addition, because infants are naturally exposed to HIB or other pathogenic bacteria, their antibody concentration will gradually increase in the early time. As a result, the incidence rate of HIB invasive diseases is quite low among newborns. However, along with the decline of antibody concentration, the incidence rate reaches the highest point in the middle childhood. In addition, the incidence rate gradually declines with immune system becoming increasingly complete. Therefore, HIB infection generally happens on children below five years old. More specifically, the incidence mainly happens to children below two years old. The distribution of HIB infection seasons shows a double-peak in winter and autumn as one peak and spring as the other peak. Generally speaking, the incidence rate is the highest in winter and the lowest in summer.

At present, there is still no national statistical data on HIB diseases in China. According to a large-scale epidemiology investigation held in Hefei, the incidence rate of HIB meningitis was 107/100,000,000 among children below five years old in Hefei and the fatality rate was 9.7%. After treated, 21.4% survival children still suffer nervous or nervous system complications or sequelae. According to the epidemiology investigation in Hefei, CRI predicts that the incidence rate of HIB invasive meningitis is 104/100,000,000 among children below five years old. However, the incidence rate of HIB diseases among all people is still not clear.

HIB vaccines still belong to Vaccine II in China, so children are inoculated HIB vaccines at the expenses of their parents voluntarily. In 2012, China's lot release volume of HIB vaccines was 32.4098 million doses, increasing by 34.84% YOY, with the market scale exceeding CNY 2 billion.

As free vaccines that are widely applied in developed countries, HIB vaccines have extremely huge development space in China. CIR predicts that HIB vaccines are likely to become Vaccine I in the coming years.

Through this report, readers can acquire the following information:

  • Development environment of China HIB vaccine industry
  • Epidemic situation of HIB diseases in China
  • Supply and demand of HIB vaccines in China
  • Major manufacturing enterprises in China HIB vaccine market

Forecast on China HIB vaccine market, 2013-2017

The following enterprises and people are proposed to purchase this report:

  • Vaccine manufacturing enterprises
  • Medical institutions
  • Investors and research institutes concerned about China vaccine industry

Table of Contents

1. Development Environment of China Vaccine Industry, 2008-2013

  • 1.1. Economic Environment
  • 1.2. Policy Environment of Vaccines
  • 1.3. Chinese Population and the Structure
  • 1.4. Overview on China Medical Industry
  • 1.5. Overview on China Vaccine Market, 2008-2017
    • 1.5.1. Market Status
    • 1.5.2. Development Forecast

2. Overview on China HIB Vaccine Industry, 2008- 2012

  • 2.1. Epidemic Situation of HIB Infection in China
    • 2.1.1. Overview
    • 2.1.2. HIB Incidence Status
  • 2.2. Overview on HIB Conjugate Vaccines
  • 2.3. China's Rules on Vaccination Procedures of HIB Vaccines

3. Analysis on China HIB Vaccine Market

  • 3.1. Supply Status
    • 3.1.1. Production Capacity
    • 3.1.2. Status of Lot Release
  • 3.2. Market Demand
    • 3.2.1. Demand Overview
    • 3.2.2. Market Scale

4 Major Manufacturing Enterprises in China HIB Vaccine Market, 2010-2013

  • 4.1. Lanzhou Institute of Biological Products Co., Ltd.
    • 4.1.1. Enterprise Profile
    • 4.1.2. Lot Release Volume of HIB Vaccines
    • 4.1.3. Production Capacity of HIB Vaccines, 2013
  • 4.3. Sanofi Pasteur
  • 4.4. GSK China
  • 4.5. Novartis Vaccines and Diagnostics S.R.L.

5. Forecast on China HIB Vaccine Industry, 2013-2017

  • 5.1. Factors Influencing Development
  • 5.2. Supply Forecast
  • 5.3. Demand Forecast

Selected Charts

  • Chart Disposable Income Per Capita of Chinese Residents, 2008-2012
  • Chart Chinese Population Size, 2001-2012
  • Chart Chinese Newborn Population Size, 2001-2012
  • Chart Market Scale of China Vaccine Market, 2008-2012
  • Chart China's Lot Release Volume of HIB Conjugate Vaccines, 2010-2012
  • Chart Factory Prices of Major HIB Vaccines in China Market, 2013
  • Chart Market Scale of HIB Vaccines in China, 2010-2012
  • Chart Lot Release Volume of HIB Vaccines of Lanzhou Institute of Biological Products Co., Ltd., 2010-2012
  • Chart Lot Release Volume of HIB Vaccines of Walvax Biotechnology Co., Ltd., 2010-2012
  • Chart Forecast on Market Scale of HIB Vaccines in China, 2013-2017
Back to Top